Analysis of the Strong Performance of Kangzhi Pharmaceutical (300086): Driven by Children's Medicine Concept and Hainan Policies

Kangzhi Pharmaceutical (300086) entered the strong stock pool today. The core drivers of its strong short-term performance include increased attention to the children’s medicine segment and favorable policies of the Hainan Free Trade Port [3][6]. On November 14, 2025, the company achieved a 20% daily limit, with a closing price of 10.62 yuan and a turnover of 107 million yuan [1].

As a pharmaceutical enterprise focusing on the R&D and production of children’s medicine, Kangzhi Pharmaceutical has significantly benefited from the recent rotation in the pharmaceutical sector: market funds have gradually shifted from high-valued tech sectors to low-valued pharmaceutical sectors, and children’s medicine as a niche segment has become a key focus for capital allocation [3][6]. In addition, the company’s business layout in Hainan allows it to enjoy policy dividends related to the Free Trade Port, further strengthening market expectations [3].

It should be noted that the company faces certain pressure on its fundamentals: its performance in the first three quarters of 2025 decreased by 10.29% year-on-year [2]. Investors should comprehensively consider short-term concept-driven factors and long-term fundamental conditions to make rational investment decisions.